Book Online
or Call 1-855-SAUSALITO
Sign In
|
Register
|
About Sausalito
|
Contact Us
Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast
|
Traffic
Online Reservations
Cavallo Point
Casa Madrona
The Gables Inn
Mill Valley Inn
Acqua Hotel
Larkspur Hotel
Waters Edge
The Lodge at Tiburon
Sausalito Hotels
Vacation Packages
San Francisco Hotels
Event Calendar
Art Galleries
Arts and Culture
Amusement Parks
Nightlife
Attractions
Sausalito Ferry
Public Parks
Entertainment
Movie Show Times
TV Listings
Celebrities on TV
Museums and Historical Places
Environmental
Food and Wine
Day Trips
Visit San Francisco
Spas and Massage
Apartments
Arts, Culture, & Entertainment
Amusement and Water Parks
Art Galleries & Dealers
Art Instruction & Schools
Attractions
Environmental
Food and Wine Entertainment
Marin Arts and Culture
Movie Theaters & Movie Rentals
Museums
Music Venues
Photographers
Photography - Commercial
Automotive
Auto Glass & Detailing
Auto Repair Service
Gas Stations
New & Used Car Dealers
Boating
Boat Rides
Boat Storage
Boats & Chartered Boats
Harbors, Marinas & Yacht Clubs
Private Yacht Clubs
Business & Professional Services
Employment Agencies
Industrial Supplies & Services
Insurance Agents & Agencies
Mailing & Shipping
Photography - Commercial
Private Investigators
Rubbish & Garbage Removal
Security Systems
Self Storage
Community & City Services
Chamber of Commerce
City & County Government
City Hall
City Maps & Guides
City of Sausalito
Community Centers
Fire Department
Library
Police Department
Post Offices
State Government
Construction and Contractors
Architects
General Contractors
Home Remodeling
Landscaping
Plumbers
Education and Schools
Nursery Schools & Kindergarten
Private Schools
Public Schools
Tutoring
Financial and Legal Services
Accountants & Tax
Banks
Bookkeeping
Financial Consultants
Lawyers & Attorneys at Law
Public Notaries
Health & Child Care
Acupuncture / Alternative Medicine
Child Protective Services
Chiropractors
Day Care
Dentists
Doctors, Physicians & Surgeons
Eye Care
Health Care Professionals
Home Health Care
Hospitals & Clinics
Hypnotherapy
Medical Equipment
Physical Therapists
Psychiatrists & Therapists
Specialists
Home and Garden
Cleaning Services
Doors & Windows
Floor Coverings
Interior Design
Landscaping
Moving Companies
Pools, Spas & Saunas
Remodeling
Media
Local TV Stations
Magazine Publishers
Newspapers
Online Publications
Print Publications
Radio Stations
Nightclubs & Music
Organizations, Foundations, & Associations
Business/Professional
Charitable Foundations
Common Interest Groups
Non-Profits
Youth Organizations
Pets
Dog & Cat Grooming
Kennels & Pet Boarding
Pet Hospitals
Pet Supplies
Veterinarians
Real Estate
Apartments
Appraisers
Commercial Development
Commercial Management
Commercial Real Estate
Construction
Developers
Mortgage Brokers
Property Management
Residential Real Estate
Religion
Restaurants, Food & Bars
American
Bakery
Breakfast
Burgers
Chinese
Coffee & Caf�s
Deli
Fast Food
Free Wi-Fi
French
Himalayan
Ice Cream / Frozen Yogurt
Indian
Italian
Mexican
Ocean View Restaurants
Pizza
Seafood
Sports Bars
Steakhouse
Sushi
Thai Food
Wine Tasting Room
Salons, Spas, & Fitness
Barbers
Beauty Salons
Cosmetics
Fitness Equipment
Gyms & Health Clubs
Manicures & Pedicures
Massages
Personal Trainers
Spas
Waxing
Sausalito Hotels & Inns
Bed & Breakfasts
Hotels, Motels & Resorts
Vacation Rentals
Shopping
Book Stores
Children's Clothing
Electronics
Florists
Furniture & Appliances
Gifts & Specialty Shops
Grocery Stores
Handbags
Jewelers
Marin County Shopping Centers
Men & Women's Clothing
Men's Clothing
Shoes
Sportswear
Women's Clothing
Yoga
Sports and Recreation
Bicycle Rentals & Retailers
Boats & Chartered Boats
Kayaking
Public Parks
Walking Trails
Technology & Utility Services
Computer Parts & Supplies
Computer Repair
Electric Companies
Internet Service Providers
Telephone & Cable Companies
Website Development & Design
Travel and Transportation
Airport Transportation
Bike Rentals
Buses Charter & Rental
Ferry
Limo Car Services
Taxi Cabs
Travel Agencies
Weddings
Caterers
Planners
Venues
Wi-Fi Hotspots
Your Business Here
Ferry Schedule
Surf Report
Coupons
Contests
Classifieds
Site Forums
Photo Gallery
Story Archives
Advertise With Us
Free Email
Send Flowers
Search Hotels in Sausalito
CHECK-IN:
CHECK-OUT:
ROOMS:
1
2
3
4
Find A Business
or
Browse Listings
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MorphoSys AG - American Depositary Shares
(NQ:
MOR
)
18.96
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MorphoSys AG - American Depositary Shares
< Previous
1
2
3
4
Next >
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
March 22, 2022
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell...
From
MorphoSys AG
Via
AccessWire
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 16, 2022
From
MorphoSys AG
Via
Business Wire
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
March 15, 2022
BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)...
From
MorphoSys AG
Via
AccessWire
Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
March 10, 2022
Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR);(NASDAQ:MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm...
From
MorphoSys AG
Via
AccessWire
MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021
March 10, 2022
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR)...
From
MorphoSys AG
Via
AccessWire
MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
January 24, 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 24, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report,...
From
MorphoSys AG
Via
AccessWire
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
January 18, 2022
- Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million ( € 66.9 million) - Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 million PLANEGG / MUNICH,...
From
MorphoSys AG
Via
AccessWire
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / Janauary 10, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40...
From
MorphoSys AG
Via
AccessWire
MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis
December 12, 2021
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis - Data presented during poster and oral sessions at the 63rd...
From
MorphoSys AG
Via
AccessWire
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
December 11, 2021
- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies - Results from the retrospective cohort analysis indicate...
From
MorphoSys AG
Via
AccessWire
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
December 11, 2021
From
Incyte
Via
Business Wire
Corporate Calendar 2022
November 29, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022 Dear Madam/Sir, Please note MorphoSys' financial reporting dates 2022 as follows: Publication of Interim Statement /...
From
MorphoSys AG
Via
AccessWire
MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results
November 11, 2021
- Monjuvi U.S. net product sales of US$ 22.0 million (€ 18.6 million), 22% growth Q-Q - Ten abstracts, including two oral presentations, accepted at upcoming ASH - Pelabresib data for arm 3 of MANIFEST...
From
MorphoSys AG
Via
AccessWire
MorphoSys Announces Departure of Roland Wandeler
November 09, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 9, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating...
From
MorphoSys AG
Via
AccessWire
MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting
November 04, 2021
Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November...
From
MorphoSys AG
Via
AccessWire
MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
November 04, 2021
- Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, including translational...
From
MorphoSys AG
Via
AccessWire
MorphoSys AG Announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the Upcoming Conference Call on November 11, 2021
November 02, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to €...
From
MorphoSys AG
Via
AccessWire
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
October 20, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating...
From
MorphoSys AG
Via
AccessWire
MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease
October 11, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food...
From
MorphoSys AG
Via
AccessWire
MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
August 26, 2021
-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL -...
From
MorphoSys AG
Via
AccessWire
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
August 26, 2021
From
Incyte
Via
Business Wire
MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
August 17, 2021
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 17, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announced today that Incyte, its development and commercialization partner for tafasitamab, entered into...
From
MorphoSys AG
Via
AccessWire
MorphoSys AG Reports Second Quarter and First Half 2021 Results
July 29, 2021
- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q - MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals - Announced and...
From
MorphoSys AG
Via
AccessWire
MorphoSys AG to Update Financial Guidance for 2021 and Reduce Financial Liabilities
July 26, 2021
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR)...
From
MorphoSys AG
Via
AccessWire
Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021
July 21, 2021
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies,...
From
MorphoSys AG
Via
AccessWire
MorphoSys Concludes a US $100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma
July 16, 2021
PLANEGG, GERMANY / ACCESSWIRE / July 16, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a...
From
MorphoSys AG
Via
AccessWire
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
July 15, 2021
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG...
From
MorphoSys AG
Via
AccessWire
Topics
Earnings
MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
July 01, 2021
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino...
From
MorphoSys AG
Via
AccessWire
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 25, 2021
- If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union - The positive opinion from the CHMP is...
From
MorphoSys AG
Via
AccessWire
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 25, 2021
From
Incyte
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
About Us
|
Contact Us
|
Privacy Policy
|
User Agreement
|
Advertise With Us
|
Site Map
Sausalito Home
|
Lodging
|
Sausalito Restaurants
|
Things To Do
|
Sausalito Events Calendar
|
Shopping
|
Sausalito Real Estate
|
Sausalito Directory Listings
|
Sausalito Blog
|
Jobs
|
More
Photos copyright by
Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.
